

Table 1. Reported cases of hyperammonemia in *Ureaplasma*-infected patients in the setting of hematopoietic stem cell transplant

ID	Age / Sex	Hematologic Diagnosis	Stem Cell Transplant Details	GvHD Prophylaxis / Immunosuppression	Induction / Salvage Chemotherapy Regimens	Antibiotics	Other Treatments	Outcome
Arber (2007) ²	28/M	DLBCL	NMA, MRD HSCT	ATG, CyA, MTX, (prednisone for cGvHD)	CHOP, ESHAP, BEAM	DOX	IVIG	Recovery
Graetz (2018) ⁷	21/M	AML	MAC, MUD HSCT	CyA, MTX	Not Reported	AZT, LEV	RFX, LLS, DFB	Recovery
Watanabe (2019) ⁸	49/M	Non-Hodgkin's Lymphoma	NMA, MUD HSCT	Tacrolimus, MTX	CEPP	CFX	N/A	Death
Ruan (2022) ⁹	16/M	Thalassemia	HSCT Details Not Reported	Not Reported	Not Reported	AZT	N/A	Death
Delafoy (2022) ¹⁰	15/F	B-ALL	MAC, Haploidentical HSCT	Not Reported	Not Reported	LEV, AZT	HD	Recovery
Current Case	32/F	B-ALL	MAC, Haploidentical HSCT	ATG, Sirolimus, CellCept, Prednisone,	AL4 / Blinatumomab	VAN, MEM	RFX, LLS, HD	Death

Abbreviations: AZT, azithromycin; CFX, ciprofloxacin; CyA, cyclosporine A; DFB, defibrotide; DLBCL, diffuse Large B-cell Lymphoma; DOX, doxycycline; HD, hemodialysis; LEV, levofloxacin; LLS, lactulose; MAC, myeloablative conditioning; MEM, meropenem, MRD, matched related donor; MTX, methotrexate.; MUD, matched unrelated donor; NMA, non-myeloablative conditioning; RFX, rifaximin; RIC, reduced-intensity conditioning; VAN, vancomycin